Stifel Nicolaus has reaffirmed its Hold rating on Johnson & Johnson (JNJ) with a price target of $260.00, according to a report released today. Analyst Rick Wise, who covers the healthcare sector, maintained this stance despite recent market movements. Wise has an average return of -0.3% and a 49% success rate, focusing on stocks like Atricure and Becton Dickinson.
Johnson & Johnson recently reported its earnings for the quarter ending June 28, with quarterly revenue of $25.31 billion and a net profit of $5.53 billion. This compares to the previous year's revenue of $23.74 billion and a net profit of $5.54 billion. The earnings show a slight increase in revenue but a nearly flat net profit year-over-year.
While Stifel Nicolaus and Bank of America Securities have both issued Hold ratings on JNJ, Leerink Partners maintained a Buy rating today. Additionally, corporate insider sentiment is currently negative, with an increase in insider selling over the past quarter. Notably, EVP and WW Chair of MedTech, Timothy Schmid, sold 33,597 shares worth approximately $9.23 million last month.